Cargando…

Safety and effectiveness of rapid-acting intra-muscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study

OBJECTIVE: The objective of this study was to evaluate the safety and effectiveness of rapid-acting intramuscular (IM) olanzapine in the treatment of acute agitation associated with schizophrenia in real-world clinical settings in Japan. METHODS: In this multicenter, postmarketing surveillance (PMS)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katagiri, Hideaki, Taketsuna, Masanori, Kondo, Shinpei, Kajimoto, Kenta, Aoi, Etsuko, Tanji, Yuka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769586/ https://www.ncbi.nlm.nih.gov/pubmed/29391799 http://dx.doi.org/10.2147/NDT.S147124

Ejemplares similares

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
por: Katagiri, Hideaki, et al.
Publicado: (2018)

Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study
por: Nishikawa, Atsushi, et al.
Publicado: (2016)

A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation
por: Katagiri, Hideaki, et al.
Publicado: (2013)

Erratum: A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation
por: Katagiri, Hideaki, et al.
Publicado: (2014)

Coadministration of intramuscular olanzapine and benzodiazepines in agitated patients with mental illness
por: Williams, Andrew M.
Publicado: (2018)

Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan
por: Ye, Wenyu, et al.
Publicado: (2011)

Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
por: Ye, Wenyu, et al.
Publicado: (2012)

A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular levomepromazine in agitated elderly patients with schizophrenia
por: Suzuki, Hidenobu, et al.
Publicado: (2013)

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
por: Ye, Wenyu, et al.
Publicado: (2012)

Use of olanzapine to treat agitation in traumatic brain injury: study protocol for a randomised controlled trial
por: Phyland, Ruby K, et al.
Publicado: (2020)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
por: Di Lorenzo, Rosaria, et al.
Publicado: (2010)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
por: Citrome, Leslie
Publicado: (2009)

Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
por: Dilla, Tatiana, et al.
Publicado: (2014)

IVIVC from Long Acting Olanzapine Microspheres
por: D'Souza, Susan, et al.
Publicado: (2014)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
por: Lindenmayer, JP
Publicado: (2010)

Pharmacokinetics of olanzapine long-acting injection: the clinical perspective
por: Heres, Stephan, et al.
Publicado: (2014)

Intramuscular midazolam, olanzapine, or haloperidol for the management of acute agitation: A multi-centre, double-blind, randomised clinical trial
por: Chan, Esther W., et al.
Publicado: (2021)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
por: Wehring, Heidi J., et al.
Publicado: (2011)

A study on blood pressure changes following Olanzapine Long Acting Injection (LAI) in schizophrenia
por: Gakkhar, Shivam, et al.
Publicado: (2022)

Pharmacological Emergency management of Agitation in Children and Young people: protocol for a randomised controlled trial of intraMuscular medication (PEAChY-M)
por: Bourke, Elyssia M, et al.
Publicado: (2023)

Phase 2 randomized placebo‐controlled study of lasmiditan for the acute treatment of migraine in Japanese patients
por: Sakai, Fumihiko, et al.
Publicado: (2021)

Second-Generation Parenteral Antipsychotic (Olanzapine) as a First-Line Treatment for Acute Undifferentiated Agitation in the Emergency Department in Comparison With Haloperidol
por: Singh, Adheera P, et al.
Publicado: (2023)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
por: Ascher-Svanum, Haya, et al.
Publicado: (2014)

Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
por: Ciudad, Antonio, et al.
Publicado: (2013)

Paroxetine combined with olanzapine in the treatment of schizophrenia
por: Wang, Ning, et al.
Publicado: (2020)

Effectiveness of drug postmarketing all-case surveillance as a safety measure in Japan
por: Kondo, Hideyuki, et al.
Publicado: (2021)

Economic Evaluation of Midazolam–Droperidol Combination, Versus Droperidol or Olanzapine for the Management of Acute Agitation in the Emergency Department: A Within-Trial Analysis
por: Yap, Celene Y. L., et al.
Publicado: (2017)

Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia
por: Lu, Mong-Liang, et al.
Publicado: (2016)

Relationship Between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients With Schizophrenia
por: An, Huimei, et al.
Publicado: (2022)

Postmarketing pharmacovigilance: Remdesivir and cardiovascular events
por: Sullivan, John T.
Publicado: (2022)

Postmarketing Safety Study Tool: A Web Based, Dynamic, and Interoperable System for Postmarketing Drug Surveillance Studies
por: Sinaci, A. Anil, et al.
Publicado: (2015)

On Agitation
Publicado: (1920)

Effects of insulin changes on quality of life and glycemic control in Japanese patients with type 2 diabetes mellitus: The insulin‐changing study intending to gain patients' insights into insulin treatment with patient‐reported health outcomes in actual clinical treatments (INSIGHTs) study
por: Ishii, Hitoshi, et al.
Publicado: (2013)

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases
por: Detke, Holland C, et al.
Publicado: (2010)

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism
por: McDonnell, David P, et al.
Publicado: (2010)

A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection
por: Atkins, Susan, et al.
Publicado: (2014)

Worth the Weight? Olanzapine Prescribing in Schizophrenia. A Review of Weight Gain and Other Cardiometabolic Side Effects of Olanzapine
por: Fitzgerald, Ita, et al.
Publicado: (2021)

The Importance of Registries in the Postmarketing Surveillance of Surgical Meshes
por: Köckerling, Ferdinand, et al.
Publicado: (2018)

Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use
por: Crawford, Melissa, et al.
Publicado: (2020)

EU postmarket surveillance plans for medical devices
por: Pane, Josep, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3qqmba4dtk4tvcklkccrh84nhu